Abstract
153 patients suffering from recurrent pathologies, i.e. viral infections (keratitis, keratouveitis, genital and labial herpes) uveitis, cystitis, and candidiasis were treated with in vitro produced transfer factor (TF) specific for HSV-1/2, CMV and Candida albicans. The cell-mediated immunity of seropositive patients to HSV-1/2 and/or CMV viruses was assessed using the leucocyte migration inhibition test (LMT) and lymphocyte stimulation test (LST) in presence of the corresponding antigens, and the frequency of positive tests before, during and after TF administration was studied. The data were stratified per type of test, antigen and the recipients’ pathology, and statistically evaluated. For the LMT, a total of 960 tests were carried out for each antigen dilution, 3 different antigen dilutions were used per test. 240/960 tests (25.4%) were found positive during non-treatment or treatment with unspecific TF, whereas 147/346 tests (42.5%) were found positive when the antigen corresponding to the specificity of the TF administered to the patient was used (P<0.001). When the data were stratified following pathology, a significant increased incidence of positive tests during specific treatment was also observed (0.0001<P<0.05). In the LST (1174 tests), a significant increase of thymidine uptake was observed in the absence of antigen (control cultures), during treatment with both specific and unspecific TF, but also in the presence of antigen and/or autologous serum during specific TF administration (P<0.0001). TF administration also significantly increased the soluble HLA class I antigens level in 40 patients studied to this effect.
Similar content being viewed by others
Abbreviations
- aut.s.:
-
autologous serum
- c.equ.:
-
cell equivalent
- CMI:
-
cell-mediated immunity
- CMV:
-
cytomegalovirus
- Con-A:
-
Concanavalin-A
- dpm:
-
disintegration per minute
- HSV-1/2:
-
herpes simplex virus type 1 and 2
- sHLA-I:
-
soluble HLA-class I antigens
- KU:
-
keratouveitis
- LMT:
-
leucocyte migration inhibition test
- LST:
-
lymphocyte stimulation test
- MI:
-
migration index
- PBL:
-
peripheral blood lymphocytes
- RC:
-
recurrent cystitis
- SI:
-
stimulation index
- TCCB:
-
transitional cell carcinoma of the bladder
- TF:
-
transfer factor
- TF-U:
-
Unspecific transfer factor
- TF-S:
-
specific transfer factor
- U:
-
uveitis
References
Lawrence HS: The cellular transfer of cutaneous hypersensitivity to tuberculin in man. Proc Soc Exp Biol Med 1949; 71: 516–22.
Lawrence HS: The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes. J Clin Inv 1955; 34: 219–30.
Fudenberg HH: Transfer factor: past, present and future. Ann R Pharm 1989; 29: 475–516.
Wilson GB, Fudenberg HH & Horsmanheimo M. Effects of dialyzable leukocyte extracts (DLE) with transfer factor activity (TF) on leukocyte migration in vitro. Antigen-dependent inhibition and antigen-independent inhibition and enhancement of migration. J La Cl Med 1979; 93: 800–18.
Borkowsky W & Lawrence HS. Effects of human leukocyte dialysates containing transfer factor in direct Leukocyte Migration Inhibition (LMI) assay. J Immunol 1979; 123: 1741–48.
Wilson GB, Metcalf JF & Fudenberg HH. Treatment of Mycobacterium fortuitum pulmonary infection with transfer factor (TF): New methodology for evaluating TF potency and predicting clinical response. Clin Imm Im 1982; 23: 478–91.
Pizza G, Viza D, Boucheix C & Corrado F: In vitro production of a transfer factor specific for transitional cell carcinoma of the bladder. Br J Canc 1976; 33: 606–11.
Pizza G, Viza D, Boucheix C & Corrado F: Effect of in vitro produced transfer factor on the immune response of cancer patients. Eur J Canc 1977; 13: 917–23.
Ascher MS, Schneider WJ, Valentine FT & Lawrence HS. In vitro properties of leukocytes dialysates containing transfer factor. Proc Nat Acad Sci 1974, 71: 1178–81.
Hamblin A, Maini RN & Dumonde DC. Antigen-dependent augmentation of lymphocyte transformation by dialyzable transfer factor. In: Ascher MS, Gottlieb AA, Kirkpatrick CH eds. Transfer Factor. Basic properties and clinical application. New York: Academic Press, 1976; 49–57.
Arala-Chaves MP: Transfer Factor in vitro. Int Arch Allergy 1974; 612–616.
Salaman MR: An investigation into the antigen-specificity of transfer factor in its stimulatory action on lymphocyte transformation. Immunology 1978; 35: 247–56.
Littman BH, Hirschman EM & David JR. Augmentation of 3H- thymidine incorporation by human lymphocytes in the presence of antigen and fractions of dialyzable transfer factor: a non specific phenomenon. Cell Immun 1977; 28: 158–66.
Burger DR, Vanderbark AA, Dunnick W, Kraybill WG & Vetto M. Properties of human transfer factor from KLH-immunized donors: dissociation of dermal transfer and proliferation augmenting activities. J Reticuloend Soc 1978; 24: 385–402.
Ascher MS & Andron LA. Transfer factor in vitro: non specificity of components that enhance lymphocyte proliferation to antigen. Clin Imm Im, 1979; 12: 72–81.
Steele RW, Myers MG & Vincent MM. Transfer factor for the prevention of varicella zoster infection in childood leukemia. N Eng J Med 1980; 303: 355–59.
Rosenfeld F, Viza D, Phillips J, Vich JM, Binct O & Aron-Brunetière R. Traitement des infections herpétiques par le facteur de transfert. Presse Méd 1984; 13: 537–40.
Viza D, Rosenfeld F, Phillips J, Vich JM, Denis J, Bonissent JF & Dogbe K. Specific bovine transfer factor for the treatment of herpes infections. In: Kirkpatrick CH, Burger DR, Lawrence HS, eds. Immunobiology of transfer factor. New York: Academic Press, 1983; 245–59.
Dwyer JM: The use of antigen specific transfer factor in the management of infections with herpes viruses. In: Kirkpatrick CH, Burger DR, Lawrence HS eds. Immunobiology of Transfer Factor. New York: Academic Press, 1983: 233–42.
Viza D, Vich JM, Phillips J & Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphok Res 1985; 4: 27–30.
Viza D, Vich JM, Phillips J, Rosenfeld F & Davies DAL. Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immun 1986; 100: 555–62.
Pizza G, De Vinci C & Fudenberg HH. Transfer Factor in malignancy. In: Jucker E, ed. Progress in Drug Research. Boston: Birkhauser Verlag Basel, 1994; 42: 401–21.
Puppo F, Brenci S, Lanza L, Bosco O, Imro MA, Scudeletti M, Indiveri F & Ferrone S. Increased level of serum HLA class I antigens in HIV infection. Human Immun 1994; 40: 259–66.
Alvarez-Cermeno JC, Casado C, Villar LM, Ferreira A, Varela JM, Dominguez M, Bootello A, Najera R & Gonzalez-Porqui P. Soluble class I antigens (sHLA) in CSF and serum of patients with HIV infection. Acta Neurol Scand 1990; 82: 14–20.
Sariria KK, Contini P, Indiveri F, Gross PA & Russo C. Serum HLA Class I levels in elderly humans: utilization in following the response to influenza vaccine. Human Immun 1994; 40: 202–9.
Maio M, Gulwani B, Langer JA, Kerbel RS, Duigon GJ, Fisher AN & Ferrone S. Modulation by inteferons of HLA antigens, high-molecular-weight melanoma associated antigen and inter-cellular expression by cultured melanoma cells with different metastatic potential. Canc Res 1989; 49: 2980–87.
Aulitzky WE, Grosse-Wilde H, Westhoff U, Tilg H, Aulitzky W, Gastl G, Herols M & Huber C. Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon- gamma. Clin Exp Im 1991; 86: 236–41.
Puppo F, Scudeletti M, Indiveri F & Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol Tod 1995; 16: 124–27.
Ferrone S, Yamamura M, Grosse Wilde H & Pouletty P. Summary of the serum-soluble HLA class I component in HLA 1991. In: Tsji K, Aizawa M, Sasazuki T eds. Proceedings of the Eleventh International Histocompatibility Workshop and Conference. London: Oxford Press, 1992; 1057–61.
Pizza G, Viza D, Wood J, Boucheix C, Ortolani C & Corrado F. In vitro produced transfer factor: clinical observations and antiviral activity. In: Khan A, Kirkpatrick CH, Hill NO, eds. Immune regulators in Transfer Factor. New York: Academic Press, 1979; 323–30.
Pizza G, Viza D, Ablashi DV, Jerome L, Armstrong G & Levine PH. The possible use of specific transfer factor in the treatment of patients with nasopharyngeal carcinoma. In: Grundman E, Krueger GRF, Ablashi DV Eds, Nasopharyngeal Carcinoma. Stuttgart: Fisher- Verlag, 1981: 301–7.
Levine PH, Pizza G, Cannon G, Ablashi DV, Armstrong G & Viza D. Cell-mediated immunity to Epstein-Barr virus-associated membrane antigens in patients with nasopharyngeal carcinoma. In: Grundman E, Krueger GRF, Ablashi DV eds. Nasopharyngeal Carcinoma. Stuttgart: Fisher- Verlag, 1981; 137–44
Centifanto YP, Zam ZS, McNeil JL & Kaufman HE. Leukocytes migration inhibitory factor in HSV infections. Inv Ophth V 1978; 17: 863–68.
Søberg M & Bendixen G. Human lymphocytemigration as a parameter of hypersensitivity. Acta Med Scand 1967; 181: 247–53.
Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A & Müller-Bérat N. In vitro production of transfer factor by lymphoblastoid cell lines. Transplan P 1975; VII (suppl.1): 329–33.
Viza D, Boucheix CI, Césarini JP, Ablashi DV, Armstrong G, Levine PH, Pizza G. Characterization of a human lymphoblastoid cell line, LDV/7, used to replicate transfer factor and immune RNA. Bio Cell 1982; 46: 1–10.
Pizza G, Severini G, Menniti D & De Vinci C, Corrado F: Tumour regression after intralesional injection of interleukin-2 (IL2) in bladder cancer. Preliminary report. Int J Canc 1984, 34: 359–67.
Inostroza J, Munoz P, Espinoza R, Millaqueo L, Diaz P, Leiva L & Sorensen R. Quantitation of soluble class I heterodimers and beta 2- microglobulin in patients with active pulmonary tubercolosis. Human Immun 1994; 40: 179–82.
Masi M, De Vinci C & Baricordi OR. Transfer factor in chronic mucoCutaneous candidiasis. Biotherapy, this issue.
De Vinci C, Pizza G, Cuzzocrea DE, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Masi M, Severini G, Fornarola V & Viza D. The use of transfer factor for treating female recurrent cystitis (RC): A preliminary observations. Biotherapy, this issue.
Pizza G, Viza V, De Vinci C, Palareti AP, Cuzzocrea DE, Fornarola V & Baricordi OR. Orally administered HSV-specific transfer factor (TF) prevents genital and/or labial herpes relapses. Biotherapy, this issue.
Meduri R, Campos E, Scorolli L, De Vinci C, PizzaG & Viza D. Transfer factor in recurrent ocular herpes. Biotherapy, this issue.
Schneck J, Maloy WL, Coliogan JE & Margulies DH. Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: estimation of the affinity of a T cell receptor for MHC. Cell 1989; 56: 47–55.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pizza, G., De Vinci, C., Fornarola, V. et al. In vitro studies during long term oral administration of specific transfer factor. Biotherapy 9, 175–185 (1996). https://doi.org/10.1007/BF02628677
Issue Date:
DOI: https://doi.org/10.1007/BF02628677